Riepilogo
pazienti trattati
Qualcuno ha mai tratto beneficio dalle cellule staminali?
Per la prima volta, le cellule staminali del cordone ombelicale sono state utilizzate con successo nel 1988 in Francia. Diversi anni dopo, nel 2007, questo metodo è stato introdotto anche dal Gruppo FamiCord in Polonia. Ad oggi, le cellule staminali del cordone ombelicale sono state trapiantate oltre 40.000 volte in tutto il mondo, salvando vite e salute a molte persone.
Il Gruppo FamiCord offre ai propri clienti trattamenti innovativi con le cellule staminali. Consulta l'elenco completo dei pazienti, affetti da diverse patologie, che ne hanno beneficiato.
Elenco dei pazienti
| NO. | Fonte | Tipo di fonte | Diagnosi | Settore medico | Anno di applicazione | Terapia | Paese | Età del destinatario |
|---|---|---|---|---|---|---|---|---|
| 3801 | Apheresis | Allogenico | No Data | Ematologia | 2019 | Terapia standard | Poland | 58 |
| 3802 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2019 | Terapia standard | Poland | 68 |
| 3803 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2019 | Terapia standard | Poland | 28 |
| 3804 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2019 | Terapia standard | Poland | 58 |
| 3805 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2019 | Terapia standard | Poland | 67 |
| 3806 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2019 | Terapia standard | Poland | 51 |
| 3807 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2019 | Terapia standard | Poland | 65 |
| 3808 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2019 | Terapia standard | Poland | 42 |
| 3809 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2019 | Terapia standard | Poland | 55 |
| 3810 | Apheresis | Autologo | Linfoma non-Hodgkin | Ematologia | 2019 | Terapia standard | Germania | 56 |
| 3811 | Apheresis | Autologo | Linfoma non-Hodgkin | Ematologia | 2019 | Terapia standard | Germania | 59 |
| 3812 | Apheresis | Autologo | Non-Hodgkin-Lymphoma-Relapse | Ematologia | 2019 | Terapia standard | Germania | 63 |
| 3813 | Apheresis | Autologo | Non-Hodgkin-Lymphoma-Relapse | Ematologia | 2019 | Terapia standard | Germania | 69 |
| 3814 | Apheresis | Allogenico | Osteomyelofibrosis – Other | Ematologia | 2019 | Terapia standard | Poland | 63 |
| 3815 | Apheresis | Allogenico | Other Myelofibrosis | Ematologia | 2019 | Terapia standard | Poland | 70 |
| 3816 | Apheresis | Allogenico | Other Myelofibrosis | Ematologia | 2019 | Terapia standard | Poland | 61 |
| 3817 | Apheresis | Allogenico | Other Myelofibrosis | Ematologia | 2019 | Terapia standard | Poland | 50 |
| 3818 | Apheresis | Allogenico | Paroxysmal Nocturnal Hemoglobinuria (Pnh) | Ematologia | 2019 | Terapia standard | Poland | 24 |
| 3819 | Apheresis | Allogenico | Plasma Cell Leukemia | Ematologia | 2019 | Terapia standard | Poland | 35 |
| 3820 | Apheresis | Allogenico | Polycythemia Vera-Myelofibrosis | Ematologia | 2019 | Terapia standard | Germania | 58 |
| 3821 | Apheresis | Allogenico | Post–Polycythemia Vera Myelofibrosis | Ematologia | 2019 | Terapia standard | Germania | 70 |
| 3822 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 65 |
| 3823 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 63 |
| 3824 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 69 |
| 3825 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 64 |
| 3826 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 56 |
| 3827 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 57 |
| 3828 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 63 |
| 3829 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 67 |
| 3830 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 78 |
| 3831 | Apheresis | Allogenico | Immunodeficienza primaria | Ematologia | 2019 | Terapia standard | Poland | 21 |
| 3832 | Apheresis | Allogenico | Immunodeficienza primaria | Ematologia | 2019 | Terapia standard | Poland | 19 |
| 3833 | Apheresis | Allogenico | Primary Mediastinal | Ematologia | 2019 | Terapia standard | Poland | 33 |
| 3834 | Apheresis | Allogenico | Mielofibrosi primaria | Ematologia | 2019 | Terapia standard | Poland | 46 |
| 3835 | Apheresis | Allogenico | Mielofibrosi primaria | Ematologia | 2019 | Terapia standard | Poland | 45 |
| 3836 | Apheresis | Allogenico | Mielofibrosi primaria | Ematologia | 2019 | Terapia standard | Germania | 55 |
| 3837 | Apheresis | Allogenico | Relapsed Peripheral T Cell Lymphoma | Ematologia | 2019 | Terapia standard | Poland | 65 |
| 3838 | Apheresis | Allogenico | Secondary Acute Myeloid Leukemia | Ematologia | 2019 | Terapia standard | Poland | 59 |
| 3839 | Apheresis | Allogenico | Secondary Acute Myeloid Leukemia | Ematologia | 2019 | Terapia standard | Germania | 64 |
| 3840 | Apheresis | Allogenico | Secondary Acute Myeloid Leukemia | Ematologia | 2019 | Terapia standard | Germania | 60 |
| 3841 | Apheresis | Allogenico | Secondary Acute Myeloid Leukemia At Myeloproliferative Neoplasms | Ematologia | 2019 | Terapia standard | Germania | 56 |
| 3842 | Apheresis | Autologo | Secondary Primary Central Nervous System Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 66 |
| 3843 | Apheresis | Allogenico | Anemia aplastica grave | Ematologia | 2019 | Terapia standard | Poland | 12 |
| 3844 | Apheresis | Allogenico | Anemia aplastica grave | Ematologia | 2019 | Terapia standard | Poland | 11 |
| 3845 | Apheresis | Allogenico | Anemia aplastica grave | Ematologia | 2019 | Terapia standard | Poland | 55 |
| 3846 | Apheresis | Allogenico | Immunodeficienza combinata grave | Ematologia | 2019 | Terapia standard | Poland | 1 |
| 3847 | Apheresis | Allogenico | T-Cell Acute Lymphoblastic Leukemia | Ematologia | 2019 | Terapia standard | Poland | 44 |
| 3848 | Apheresis | Autologo | T-Cell Non-Hodgkin Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 55 |
| 3849 | Apheresis | Autologo | T-Cell Non-Hodgkin Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 59 |
| 3850 | Apheresis | Allogenico | T-Cell Non-Hodgkin Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 67 |
| 3851 | Apheresis | Allogenico | T-Cell Non-Hodgkin Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 45 |
| 3852 | Apheresis | Autologo | T-Cell Non-Hodgkin Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 72 |
| 3853 | Apheresis | Autologo | T-Cell Non-Hodgkin Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 61 |
| 3854 | Apheresis | Autologo | T-Cell Non-Hodgkin Lymphoma | Ematologia | 2019 | Terapia standard | Germania | 61 |
| 3855 | Apheresis | Autologo | Testicular Cancer Relapse | Ematologia | 2019 | Terapia standard | Germania | 29 |
| 3856 | Apheresis | Allogenico | Thalassemia Major | Ematologia | 2019 | Terapia standard | Poland | 20 |
| 3857 | Apheresis | Allogenico | Wiskott-Aldrich Syndrome | Ematologia | 2019 | Terapia standard | Poland | 1 |
| 3858 | Apheresis | Allogenico | Β – Thalassemia | Ematologia | 2019 | Terapia standard | Poland | 13 |
| 3859 | Adipose Tissue | Autologo | Chondromalacia | Ortopedia | 2019 | Terapia sperimentale | Poland | 48,8 |
| 3860 | Adipose Tissue | Autologo | Chondromalacia | Ortopedia | 2019 | Terapia sperimentale | Poland | 38,6 |
| 3861 | Adipose Tissue | Autologo | Coxarthrosis | Ortopedia | 2019 | Terapia sperimentale | Poland | 34 |
| 3862 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3863 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3864 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3865 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3866 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3867 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3868 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3869 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3870 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3871 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3872 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3873 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3874 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3875 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3876 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3877 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3878 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3879 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3880 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3881 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3882 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3883 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3884 | Adipose Tissue | Autologo | Cutis Laxa | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3885 | Adipose Tissue | Autologo | Gonarthrosis | Ortopedia | 2019 | Terapia sperimentale | Poland | 44,11 |
| 3886 | Adipose Tissue | Autologo | Gonarthrosis | Ortopedia | 2019 | Terapia sperimentale | Poland | 65,3 |
| 3887 | Adipose Tissue | Autologo | Gonarthrosis | Ortopedia | 2019 | Terapia sperimentale | Poland | 68,6 |
| 3888 | Adipose Tissue | Autologo | Gonarthrosis | Ortopedia | 2019 | Terapia sperimentale | Poland | 36,1 |
| 3889 | Adipose Tissue | Autologo | Gonarthrosis | Ortopedia | 2019 | Terapia sperimentale | Poland | 54,3 |
| 3890 | Adipose Tissue | Autologo | Mild Arthritis | Ortopedia | 2019 | Terapia sperimentale | Poland | 21,2 |
| 3891 | Adipose Tissue | Autologo | Mild Arthritis | Ortopedia | 2019 | Terapia sperimentale | Poland | 68,5 |
| 3892 | Adipose Tissue | Autologo | Osteoarthritis | Ortopedia | 2019 | Terapia sperimentale | Poland | 52,8 |
| 3893 | Adipose Tissue | Autologo | Osteoarthritis | Ortopedia | 2019 | Terapia sperimentale | Poland | 44,8 |
| 3894 | Adipose Tissue | Autologo | Osteoarthritis | Ortopedia | 2019 | Terapia sperimentale | Poland | 52,5 |
| 3895 | Adipose Tissue | Autologo | Osteoarthritis | Ortopedia | 2019 | Terapia sperimentale | Poland | 54,5 |
| 3896 | Adipose Tissue | Autologo | Osteoarthritis | Ortopedia | 2019 | Terapia sperimentale | Poland | 55,11 |
| 3897 | Adipose Tissue | Autologo | Scar | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3898 | Adipose Tissue | Autologo | Scar | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3899 | Adipose Tissue | Autologo | Scar | Dermatology | 2019 | Clinical Trial | Poland | no data |
| 3900 | Adipose Tissue | Autologo | Scar | Dermatology | 2019 | Clinical Trial | Poland | no data |